| DC44809 |
AUTAC4 |
AUTAC4 is a mitochondria-targeting autophagy-targeting chimera (AUTAC). AUTAC4 downregulates cytosolic proteins and promots targeted mitochondrial turnover via mitophagy. |
|
| DC44941 |
CZC-54252 hydrochloride |
CZC-54252 hydrochloride is a potent and selective LRRK2 inhibitor with IC50s of 1.28 nM and 1.85 nM for wild-type and G2019S LRRK2, respectively. G2019S LRRK2-induced human neuronal injury is attenuated by CZC-54252 hydrochloride with an EC50 of ~1 nM.CZC-54252 hydrochloride has a neuroprotective activity. |
|
| DC45965 |
Norswertianin |
Norswertianin, a xanthone compound, serves as a powerful anti-glioma compound. Norswertianin induces GBM cells differentiation through oxidative stress and Akt/mTOR dependent autophagy. |
|
| DC46043 |
MRIA9 |
MRIA9 is an ATP-competitive, pan Salt-Inducible kinase (SIK) and PAK2/3 inhibitor, with IC50 values of 516 nM, 180 nM and 127 nM for SIK1, SIK2 and SIK3, respectively. |
|
| DC46275 |
cGMP-HTL |
cGMP-HTL contains a HT-ligand, a linker and the Cys-S-cGMP (autophagy tag). cGMP-HTL increases the K63-linked ubiquitination of mitochondria. AUTAC (autophagy-targeting chimera) is a novel targeted-clearance strategy that contains a degradation tag (guanine derivatives) and a warhead to provide target specificity. |
|
| DC46477 |
Tat-beclin 1 TFA |
Tat-beclin 1 TFA, a peptide derived from a region of the autophagy protein (beclin 1), is a potent inducer of autophagy and interacts with negative regulator of autophagy, GAPR-1 (GLIPR2). Tat-beclin 1 TFA decreases the accumulation of polyglutamine expansion protein aggregates and the replication of several pathogens (including HIV-1) in vitro, and reduces mortality in mice infected with chikungunya (CHIKV) or West Nile virus (WNV). |
|
| DC46639 |
WH-4-025
Featured
|
WH-4-025 is a Salt-inducible kinase (SIK) inhibitor (WO2016023014 A2). |
|
| DC47748 |
Autophagy-IN-C1 |
Autophagy-IN-C1 not only induces apoptosis but also blocks autophagy in hepatocellular carcinoma (HCC) cells. |
|
| DC48115 |
ATG7-IN-1 |
ATG7-IN-1 is a potent and selective inhibitor of ATG7 (IC50 = 62 nM). |
|
| DC48116 |
N6-Isopentenyladenosine |
N6-Isopentenyladenosine (Riboprine), an RNA modification found in cytokinins, which regulate plant growth/differentiation, and a subset of tRNAs, where it improves the efficiency and accuracy of translation. N6-Isopentenyladenosine, an end product of the mevalonate pathway, is an autophagy inhibitor with an interesting anti-melanoma activity. |
|
| DC48117 |
EB-42486
Featured
|
EB-42486 is a novel, potent, and highly selective G2019S-LRRK2 inhibitor (IC50 < 0.2 nM). |
|
| DC48753 |
DC-LC3in-D5 |
DC-LC3in-D5 acts as an autophagy inhibitor by attenuating LC3B lipidation. DC-LC3in-D5 binds with LC3B. DC-LC3in-D5 disrupts the LC3B-LBP2 interaction with an IC50 of 200 nM. DC-LC3in-D5 may contribute to anti-HCV or combination treatments in cancer through inhibiting autophagy. |
|
| DC48755 |
Mono-Pt |
Mono-Pt is the first platinum(II) complex that inhibits cancer cells through a non-DNA-binding mitophagy pathway. Mono-Pt promotes the occurrence of mitophagy in cancer cells via stimulating endoplasmic reticulum stress (ERS) and activating unfolded protein response (UPR). |
|
| DC48912 |
SH379 |
SH379 is the derivative of 2-methylpyrimidine-fused tricyclic diterpene. SH379 is a potent and orally active anti-late-onset hypogonadism agent. SH379 significantly promotes the expression of the key testosterone synthesis-related enzymes StAR and 3β-HSD. SH379 stimulates autophagy through regulating AMPK/mTOR signaling pathway. |
|
| DC49021 |
SH498 |
SH498, a novel Bmi-1-mediated antitumor agent, shows potent antiproliferative activity. |
|
| DC49026 |
QW24 |
QW24 exerts potent anti-tumor activity by down-regulating BMI-1 and is used as an effective therapeutic agent for clinical colorectal cancer treatment. |
|
| DC49538 |
Niacin-13C6 |
Niacin-13C6 (Nicotinic acid-13C6) is the 13C-labeled Niacin. Niacin (Nicotinic acid) is a vitamin and is part of the vitamin B group. |
|
| DC49539 |
Taurine-13C2,15N |
Taurine-13C2,15N (2-Aminoethanesulfonic acid-13C2,15N) is the 13C- and 15N- labeled Taurine. Taurine, a sulphur-containing amino acid and an organic osmolyte involved in cell volume regulation, provides a substrate for the formation of bile salts, and plays a role in the modulation of intracellular free calcium concentration. Taurine has the ability to activate autophagy in adipocytes. |
|
| DC49540 |
Taurine-13C2 |
Taurine-13C2 (2-Aminoethanesulfonic acid-13C2) is the 13C-labeled Taurine. Taurine, a sulphur-containing amino acid and an organic osmolyte involved in cell volume regulation, provides a substrate for the formation of bile salts, and plays a role in the modulation of intracellular free calcium concentration. Taurine has the ability to activate autophagy in adipocytes. |
|
| DC49541 |
LRRK2-IN-3 |
LRRK2-IN-3 (compoubd 24) is a potent, selective, orally active and brain-penetrant inhibitor LRRK2, with IC50 of 2.6 nM in human PBMCs. LRRK2-IN-3 can be used for the research of Parkinson's disease. |
|
| DC49542 |
LRRK2-IN-2 |
LRRK2-IN-2 (compoubd 22) is a potent, selective, orally active and brain-penetrant inhibitor LRRK2, with IC50 of <0.6 nM. LRRK2-IN-2 can be used for the research of Parkinson's disease. |
|
| DC70221 |
Atg4B inhibitor 21f |
Atg4B inhibitor 21f is a potent competitive inhibitor for Atg4B with Ki of 3.1 uM.Atg4B inhibitor 21f enhanced the anticancer activity of anti-CRPC drugs via autophagy inhibition. |
|
| DC70343 |
DCC-3116
Featured
|
DCC-3116 (DCC3116) is a first-in-class, selective inhibitor of ULK1/2 kinases (IC50=4.7/35 nM) and autophagy.DCC-3116 is an oral ULK1/2 inhibitor targeting the autophagy pathway, a key mechanism of tumor survival and resistance to targeted therapy. |
|
| DC70422 |
G2019S-LRRK2 inhibitor 38 |
G2019S-LRRK2 inhibitor 38 is a potent, selective, brain penetrant G2019S-LRRK2 kinase inhibitor with IC50 of <1 nM, cellular EC50 of 40 nM, >2,000-fold selectivity over WT LRRK2 (cellular EC50>100 uM).G2019S-LRRK2 inhibitor 38 selectively inhibit phosphorylation of Ser935 in vitro, and in brain, lung, kidney and spleen in G2019S-LRRK2 mice. |
|
| DC70857 |
UAMC-2526 |
UAMC-2526 (UAMC2526) is a low micromolar ATG4B and autophagy inhibitor.UAMC-2526 (50-100 uM) completely inhibits proliferation of HT-29 colorectal carcinoma cells.UMAC-2526 inhibits autophagy in a colorectal cancer xenograft model and potentiates chemotherapy efficacy.UMAC-256 inhibits autophagy in a healthy mouse model, animals treated withcompound UAMC-2526 showed lower levels of uncleaved (free) GFP, decreased LC3-II/LC3-I ratios and a marked increase of SQSTM1.UAMC-2526 combined with gemcitabine significantly reduced tumor growth as compared to the individual treatments, did not inhibit autophagy in the Panc02 mouse model. |
|
| DC71101 |
PF-06456384 |
PF-06447475 is a highly potent, selective, brain penetrant LRRK2 kinase inhibitor with IC50 values of 3 nM and 11 nM for WT LRRK and G2019S LRRK2, respectively. PF-06447475 can be used for parkinson's disease (PD) research. |
|
| DC71297 |
ARN5187 trihydrochloride |
ARN5187 trihydrochloride is a lysosomotropic REV-ERBβ ligand with a dual inhibitory activity toward REV-ERB-mediated transcriptional regulation and autophagy. ARN5187 trihydrochloride shows lysosomotropic potency and cytotoxicity. ARN5187 trihydrochloride induces apoptosis. |
|
| DC72017 |
XL01126 |
XL01126 is a potent degrader of LRRK2 with DC50s of 14 nM (G2019S LRRK2) and 32 nM (WT LRRK2), respectively. XL01126 can cross blood-brain barrier and be used as a degrader probe in Parkinson’s disease research. XL01126 exerts function of study of non-catalytic and scaffolding functions of LRRK2. |
|
| DC72134 |
Forigerimod |
Forigerimod (IPP-201101) is a CD4 T-cell modulator. Forigerimod is a 21-amino-acid fragment of U1 small nuclear ribonucleoprotein 70 kDa that is phosphorylated at Ser140. Forigerimod can potently inhibit autophagy. Forigerimod can be used for the research of autoimmune disorders, such as systemic lupus erythematosus (SLE) . |
|
| DC72163 |
MPM-1 |
MPM-1, a marine Eusynstyelamides mimic, is a potent anticancer agent. MPM-1 can rapidly kill cancer cells in vitro by inducing a necrosis-like death. MPM-1 has the ability to induce immunogenic cell death. MPM-1 causes perturbation of autophagy and lysosomal swelling in cancer cells. |
|
